Loading data for TMDX — first visit, this takes a few seconds.

TransMedics Group, Inc.

NasdaqGM: TMDX · Real-Time Price · USD
89.98
+3.00 (3.45%)
At close: Sep 04, 2026, 8:00 PM
89.88
-0.11%
After-hours: 7:51 PM

The price, the headline numbers and the latest news, in one place.

TransMedics Group, Inc. (TMDX) Stock Price, Analysis & Data

No data available

Bid55.39
Market Cap3.12B
Revenue (ttm)668M
Net Income (ttm)152M
1.88
3.86
23.31
39.03
P/B (ttm)6.01
P/S (ttm)4.65
Earnings DateOct 29, 2026
Ask87.47
Volume542,547
Avg. Volume (20D)936,284
Open84.69
Previous Close86.98
Day's Range83.61 - 90.11
52-Week Range60.10 - 156.00
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body....

Sector Healthcare
IPO Date May 2, 2019
Employees 898
Stock Exchange NasdaqGM
Ticker Symbol TMDX
Full Company Profile

Financial Performance

In 2025, TransMedics's revenue was 605.49M, an increase of 37.13% compared to the previous year's 441.54M. Earnings were 190.29M, an increase of 436.58%.

Financial Statements

Earnings Surprise

TransMedics has released their quarterly earnings on Aug 4, 2026:
  • Revenue of $189.95M misses estimates by $0, with 20.70% YoY growth.
  • EPS of 0.44 misses estimates by -0.04, with -52.17% YoY decline.
TransMedics Group, Inc. is scheduled to release its earnings on Oct 29, 2026, after market closes.
Analysts project revenue of ... Upgrade